Clinical Study on Tissue Preservation in Breast Augmentation and Reconstruction
Post-Marketing Clinical Follow-Up Study on Tissue Preservation Techniques in Breast Augmentation and Reconstruction.
Visão geral do estudo
Status
Descrição detalhada
This post-marketing observational study evaluates the safety and efficacy of innovative, minimally invasive breast augmentation and reconstruction techniques: Mia Harmonization, Mia Scarless Lift, Mia Reconstruction, Joy Dot, and Maxtopexia + Mia. These techniques aim to enhance tissue preservation, minimize scarring, and promote quicker recovery compared to traditional methods.
The study will enroll 60 participants undergoing these procedures at the Sulàyöm Innovation Campus in Costa Rica between January and December 2025. Participants will be followed for 36 months to monitor complication rates, tissue health, and satisfaction. Procedures utilize advanced devices like the Motiva Ergonomix2® Diamond®, Motiva Injector®, Motiva® Inflatable Balloon, and Motiva® Reusable Channel Separator, designed to optimize outcomes while preserving natural breast structures.
Key assessments include:
Safety Metrics: Monitoring adverse events, such as tissue necrosis, hematoma, or infection, through regular follow-ups.
Efficacy Metrics: Evaluating tissue preservation during and after surgery using imaging and clinical assessments.
Patient and Surgeon Satisfaction: Measuring perceptions of outcomes and procedure success using validated scales.
The study will also conduct a temperature monitoring substudy using the Motiva® Zen transponder to assess its functionality in recording implant temperature. This optional component enhances understanding of implant safety.
Results will provide crucial insights into the role of minimally invasive techniques in improving breast surgery outcomes, focusing on safety, tissue preservation, and patient satisfaction. These findings will inform future surgical practices and technological advancements.
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Locais de estudo
-
-
Alajuela Province
-
Coyol, Alajuela Province, Costa Rica, 20113
- Establishment Labs
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Método de amostragem
População do estudo
The study population comprises approximately 60 cisgender women aged 18 years or older who will undergo minimally invasive breast augmentation or benign reconstruction procedures at the Sulàyöm Innovation Campus in Costa Rica.
Eligible participants will include women with breast cup sizes ranging from AA to C, classified as ASA I or II, and with sufficient breast tissue to support implant placement. The cohort will include individuals undergoing the following procedures:
- Mia Harmonization
- Mia Scarless Lift
- Mia Reconstruction
- Joy Dot
- Maxtopexia + Mia Additionally, participants may have congenital or acquired breast conditions (e.g., amastia, tuberous breasts, asymmetry) and meet the specific inclusion criteria for these advanced minimally invasive techniques.
Recruitment will focus on women scheduled for surgery between January and December 2025, with follow-up spanning 36 months. Participants must reside in Costa Rica to ensure adherence to follow-up visits.
Descrição
Inclusion Criteria:
- Gender and Age: Cisgender women, aged 18 years or older.
Surgical Procedure: Participants undergoing primary breast augmentation or benign reconstruction using the following minimally invasive procedures:
- Mia Harmonization
- Mia Scarless Lift
- Mia Reconstruction
- Joy Dot
- Maxtopexia + Mia
- Breast Size: Cup sizes AA to C, as determined by guidelines from Triumph International.
- Health Status: ASA (American Society of Anesthesiologists) classification I or II.
- Tissue Integrity: Adequate breast tissue available to cover the implant(s).
- Commitment: Willingness to adhere to all study requirements, including follow-up visits and signing the informed consent form.
- Special Cases for Reconstruction: Participants with congenital or acquired breast or thoracic conditions, such as amastia, pectus excavatum/carinatum, tuberous breasts, or asymmetry.
- Mia Scarless Lift Specifics: Participants with mild, moderate, or pseudoptosis based on physician evaluation.
- Timing: Women scheduled for surgery at the Sulàyöm Innovation Campus between January and December 2025.
Exclusion Criteria:
- Non-Specified Procedures: Women undergoing augmentation or reconstruction with techniques other than those listed (Mia Harmonization, Mia Scarless Lift, Mia Reconstruction, Joy Dot, Maxtopexia + Mia).
- Non-Study Implants: Use of implants other than Motiva products.
Compromised Tissue or Skin:
- Existing rib lesions or significant/severe breast ptosis.
- Poor tissue quality due to radiation damage, vascular compromise, or prior ulceration.
Medical History:
- History of breast abscesses or infections.
- Sensitivity or allergy to silicone.
Current Physiological Conditions:
-Pregnancy or breastfeeding, or within six months postpartum or post-lactation.
- Medications: Use of anticoagulants or medications that impair wound healing (e.g., corticosteroids, Warfarin).
- Imaging Constraints: Conditions that prevent the use of MRI (e.g., implanted metal devices, claustrophobia).
- Concurrent Research: Participation in another clinical research study involving drugs or devices.
- Follow-Up Barriers: Residency outside Costa Rica or inability to attend required follow-up visits.
- Timing Issues: Participants undergoing surgery outside the designated study period (January to December 2025).
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
Coortes e Intervenções
Grupo / Coorte |
Intervenção / Tratamento |
|---|---|
|
Minimally Invasive Breast Surgery Cohort
This single cohort consists of approximately 60 women undergoing one of the minimally invasive breast augmentation or reconstruction procedures (Mia Harmonization, Mia Scarless Lift, Mia Reconstruction, Joy Dot, or Maxtopexia + Mia) at the Sulàyöm Innovation Campus.
Data from all participants will be analyzed collectively to evaluate the safety, efficacy, and outcomes of these procedures.
|
Minimally invasive technique for breast augmentation, increasing volume while preserving natural tissue.
Minimally invasive breast lift for mild to moderate ptosis without visible scarring.
Reconstructive technique for restoring breast contour and volume after benign surgical interventions.
Advanced augmentation method using specialized tools to preserve tissue integrity and minimize trauma.
Breast lift combining traditional techniques with advanced minimally invasive methods for tissue preservation.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of Adverse Events Related to Tissue Preservation
Prazo: 36 months post-surgery.
|
The cumulative occurrence of adverse events, such as necrosis, hematoma, infection, or tissue damage, associated with the surgical procedures.
|
36 months post-surgery.
|
|
Rate of Intraoperative Tissue Integrity Preservation
Prazo: Day of surgery.
|
Proportion (%) of surgical procedures in which intraoperative tissue integrity is maintained (no damage observed), and incidence rate (%) of tissue damage events during surgery, as assessed intraoperatively.
|
Day of surgery.
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Patient-Reported Satisfaction Score (5-Point Likert Scale)
Prazo: Baseline and follow-ups at 1, 3, 6, 12, 24, and 36 months post-surgery.
|
Mean score and distribution of patient-reported satisfaction with breast appearance, natural feel, and symmetry, measured using a 5-point Likert scale.
|
Baseline and follow-ups at 1, 3, 6, 12, 24, and 36 months post-surgery.
|
|
Surgeon-Reported Satisfaction Score (5-Point Likert Scale)
Prazo: Day of surgery.
|
Mean score and distribution of surgeon-reported satisfaction with breast appearance, natural feel, and symmetry, measured using a 5-point Likert scale.
|
Day of surgery.
|
|
Rate of Postoperative Complications
Prazo: 36 months post-surgery.
|
Incidence rate (%) of postoperative complications, including fibrosis, capsular contracture, and scarring, during the follow-up period.
|
36 months post-surgery.
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Patient-Reported Pain Score (Standardized Pain Scale)
Prazo: Baseline and follow-ups at 1, 3, 6, 12, 24, and 36 months post-surgery.
|
Mean patient-reported pain score measured using a standardized pain scale at each follow-up visit.
|
Baseline and follow-ups at 1, 3, 6, 12, 24, and 36 months post-surgery.
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- CIP-001003
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Individual Participant Data (IPD) will not be shared to ensure the confidentiality and privacy of participants. Since the study collects sensitive clinical data, strict measures are in place to protect participant identities. Data will be securely stored in a de-identified and encrypted format, accessible only to authorized research personnel. This approach aligns with ethical standards and local regulations, such as Costa Rica's Ley de Investigación Biomédica (Law 9234), which prioritizes the protection of participants' personal information.
Additionally, as this is an observational study with no direct interventions, the value of sharing IPD for broader scientific purposes is limited compared to the aggregate analysis and results.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .